Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice

Journal of Cellular Biochemistry

Volumn 112, Issue 9, 2011, Pages 2616-2626

  Vecoli, C ^a,b   Cao, J ^c   Neglia, D ^d   Inoue, K ^e   Sodhi, K ^e   Vanella, L ^f   Gabrielson, K K ^b   Bedja, D ^b   Paolocci, N ^b,g   L'Abbate, A ^a   Abraham, N G ^f  

^a SCUOLA SUPERIORE SANT ANNA   (Italy)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c CHINESE PLA GENERAL HOSPITAL   (China)

^d INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f MEDICAL COLLEGE OF OHIO   (United States)

^g UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Adiponectin; Diabetes; Heme oxygenase; Inflammation; Insulin sensitivity; Oxidative STRESS

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN A1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; HEME OXYGENASE 1; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; RECOMBINANT PEPTIDE L 4F; RECOMBINANT PROTEIN; SUPEROXIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOACCUMULATION; CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; GLUCOSE BLOOD LEVEL; HEART; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; IN VIVO CULTURE; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ADENYLATE KINASE; ADIPONECTIN; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; CARDIOTONIC AGENTS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; HEART; HEART FUNCTION TESTS; HEME OXYGENASE-1; MICE; MICE, INBRED C57BL; MICE, OBESE; MYOCARDIUM; NITRIC OXIDE SYNTHASE; PEPTIDES; SUPEROXIDES; VENTRICULAR DYSFUNCTION, LEFT;

MUS;

EID: 84860389396     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.23188     Document Type: Article

References (52)

1. Abraham NG, Kushida T, McClung J, Weiss M, Quan S, Lafaro R, Darzynkiewicz Z, Wolin M,. 2003. Heme oxygenase-1 attenuates glucose-mediated cell growth arrest and apoptosis in human microvessel endothelial cells. Circ Res 93: 507-514. (Pubitemid 37163230)
2. Berg AH, Scherer PE,. 2005. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96: 939-949. (Pubitemid 40712793)
3. Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, Movva R, Navab M, Fogelman AM, Rader DJ,. 2008. Safety, pharmacokinetics and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res 49: 1344-1352.
4. Cacho J, Sevillano J, de Castro J, Herrera E, Ramos MP,. 2008. Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. Am J Physiol Endocrinol Metab 295 (5): E1269-E1276.
5. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ,. 2002. Hyperglycemia- induced apoptosis in mouse myocardium: Mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51: 1938-1948. (Pubitemid 34564309)
6. Carley AN, Severson DL,. 2008. What are the biochemical mechanisms responsible for enhancedfatty acid utilization by perfused hearts from type 2 diabetic db/db mice? Cardiovasc Drugs Ther 22: 83-89.
7. Ceriello A, Quagliaro L, D'Amico M, Di Filippo C, Marfella R, Nappo F, Berrino L, Rossi F, Giugliano D,. 2002. Acute hyperglycemia induces nitrotyrosine formation and apoptosis in perfused heart from rat. Diabetes 51: 1076-1082. (Pubitemid 34438352)
8. Chen ZP, Mitchelhill KI, Michell BJ, Stapleton D, Rodriguez-Crespo I, Witters LA, Power DA, Ortiz de Montellano PR, Kemp BE,. 1999. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 443: 285-289. (Pubitemid 29080812)
9. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL,. 2001. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103: 2055-2059. (Pubitemid 32373007)
10. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM,. 1999. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
11. Garber DW, Venkatachalapathi YV, Gupta KB, Ibdah J, Phillips MC, Hazelrig JB, Segrest JP, Anantharamaiah GM,. 1992. Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties. Arterioscler Thromb 12: 886-894.
12. Giannessi D, Caselli C, Del Ry S, Maltinti M, Pardini S, Turchi S, Cabiati M, Sampietro T, Abraham N, L'abbate A, Neglia D,. 2010. Adiponectin is associated with abnormal lipid profile and coronary microvascular dysfunction in patients with dilated cardiomyopathy without overt heart failure. Metabolism 60: 227-233.
13. Gupte SA, Kaminski PM, Floyd B, Agarwal R, Ali N, Ahmad M, Edwards J, Wolin MS,. 2005. Cytosolic NADPH may regulate differences in basal Nox oxidase-derived superoxide generation in bovine coronary and pulmonary arteries. Am J Physiol Heart Circ Physiol 288: H13-H21. (Pubitemid 40023822)
14. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T,. 2001. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: E14-E22.
15. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y,. 2000. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20: 1595-1599. (Pubitemid 30353893)
16. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV,. 2001. Glycemic control and heart failure among adult patients with diabetes. Circulation 103: 2668-2673. (Pubitemid 32538780)
17. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K,. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 116: 1784-1792. (Pubitemid 44033298)
18. Kruger AL, Peterson S, Turkseven S, Kaminski PM, Zhang FF, Quan S, Wolin MS, Abraham NG,. 2005. D-4F induces heme oxygenase-1 and extracellular superoxide dismutase, decreases endothelial cell sloughing, and improves vascular reactivity in rat model of diabetes. Circulation 111: 3126-3134. (Pubitemid 40847791)
19. Kusmic C, L'Abbate A, Sambuceti G, Drummond G, Barsanti C, Matteucci M, Cao J, Piccolomini F, Cheng J, Abraham NG,. 2010. Improved myocardial perfusion in chronic diabetic mice by the up-regulation of pLKB1 and AMPK signaling. J Cell Biochem 109: 1033-1044.
20. L'Abbate A, Neglia D, Vecoli C, Novelli M, Ottaviano V, Baldi S, Barsacchi R, Paolicchi A, Masiello P, Drummond GS, McClung JA, Abraham NG,. 2007. Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats. Am J Physiol Heart Circ Physiol 293: H3532-H3541. (Pubitemid 350230897)
21. Lazar MA,. 2005. How obesity causes diabetes: Not a tall tale. Science 307: 373-375. (Pubitemid 40139971)
22. Maruyama S, Shibata R, Ohashi T, Ohashi K, Daida H, Walsh K, Ouchi N, Murohara T,. 2010. Adiponectin protects against doxorubicin induced cardiomyopathy through an Akt dependent mechanism. Circulation 122: A12527.
23. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ,. 2010. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 56: 1113-1132.
24. Nagareddy PR, Xia Z, McNeill JH, MacLeod KM,. 2005. Increased expression of iNOS is associated with endothelial dysfunction and impaired pressor responsiveness in streptozotocin induced diabetes. Am J Physiol Heart Circ Physiol 289: H2144-H2152. (Pubitemid 41507367)
25. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G, Lallone R, Fogelman AM,. 2002. Oral administration of an Apo A-I mimetic peptide synthesized from D -amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 105 (3): 290-292. (Pubitemid 34106174)
26. Navab M, Anantharamaiah GM, Reddy ST, Fogelman AM,. 2006. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 3: 540-547. (Pubitemid 44445797)
27. Navab M, Shechter I, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM,. 2010. Structure and function of HDL mimetics. Arterioscler Thromb Vasc Biol 30: 164-168.
28. Nicolai A, Li M, Kim DH, Peterson SJ, Vanella L, Positano V, Gastaldelli A, Rezzani R, Rodella LF, Drummond G, Kusmic C, L'Abbate A, Kappas A, Abraham NG,. 2009. Heme oxygenase-1 induction remodels adipose tissue and improves insulin sensitivity in obesity-induced diabetic rats. Hypertension 53: 508-515.
29. Peterson SJ, Husney D, Kruger AL, Olszanecki R, Ricci F, Rodella LF, Stacchiotti A, Rezzani R, McClung JA, Aronow WS, Ikehara S, Abraham NG,. 2007. Long-term treatment with the apolipoprotein A1 mimetic peptide increases antioxidants and vascular repair in type I diabetic rats. J Pharmacol Exp Ther 322: 514-520. (Pubitemid 47105774)
30. Peterson SJ, Drummond G, Kim DH, Li M, Kruger AL, Ikehara S, Abraham NG,. 2008. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J Lipid Res 49: 1658-1669.
31. Peterson SJ, Kim DH, Li M, Positano V, Vanella L, Rodella LF, Piccolomini F, Puri N, Gastaldelli A, Kusmic C, L'Abbate A, Abraham NG,. 2009. The L-4F mimetic peptide prevents insulin resistance through increased levels of HO-1, pAMPK, and pAKT in obese mice. J Lipid Res 50: 1293-1304.
32. Rask-Madsen C, King GL,. 2007. Mechanisms of disease: Endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3: 46-56. (Pubitemid 46006612)
33. Ruan X, Li Z, Zhang Y, Yang L, Pan Y, Wang Z, Feng GS, Chen Y,. 2010. Apolipoprotein A-I possesses an anti-obesity effect associated with increase of energy expenditure and upregulation of UCP1 in brown fat. J Cell Mol Med 15 (4): 763-772.
34. Russell RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ, Young LH,. 2004. AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114: 495-503. (Pubitemid 39572099)
35. Rytter L, Troelsen S, Beck-Nielsen H,. 1985. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 8: 230-234. (Pubitemid 15071437)
36. Semeniuk LM, Kryski AJ, Severson DL,. 2002. Echocardiographic assessment of cardiac function in diabetic db/db and transgenic db/db-hGLUT4 mice. Am J Physiol Heart Circ Physiol 283: H976-H982.
37. Sherman CB, Peterson SJ, Frishman WH,. 2010. Apolipoprotein A-I mimetic peptides: A potential new therapy for the prevention of atherosclerosis. Cardiol Rev 18: 141-147.
38. Shibata R, Sato K, Kumada M, Izumiya Y, Sonoda M, Kihara S, Ouchi N, Walsh K,. 2007. Adiponectin accumulates in myocardial tissue that has been damaged by ischemia-reperfusion injury via leakage from the vascular compartment. Cardiovasc Res 74: 471-479. (Pubitemid 46693703)
39. Stevens MJ,. 2005. Oxidative-nitrosative stress as a contributing factor to cardiovascular disease in subjects with diabetes. Curr Vasc Pharmacol 3: 253-266. (Pubitemid 40933048)
40. Stroedter D, Schmidt T, Bretzel RG, Federlin K,. 1995. Glucose metabolism and left ventricular dysfunction are normalized by insulin and islet transplantation in mild diabetes in the rat. Acta Diabetol 32: 235-243. (Pubitemid 26007465)
41. Sutherland FG, Shattock MJ, Baker KE, Hearse DJ,. 2003. Mouse isolated perfused heart: Characteristics and cautions. Clin Exp Pharmacol Physiol 30: 867-878. (Pubitemid 37506155)
42. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B, Lazzarino G, Paolocci N, Gabrielson KL, Wang Y, Kass DA,. 2005. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 115: 1221-1231. (Pubitemid 40629040)
43. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL,. 2007. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress. Circulation 115: 1408-1416. (Pubitemid 46648376)
44. Van Lenten BJ, Wagner AC, Jung CL, Ruchala P, Waring AJ, Lehrer RI, Watson AD, Hama S, Navab M, Anantharamaiah GM, Fogelman AM,. 2008. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J Lipid Res 49: 2302-2311.
45. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Navab M, Reddy ST, Buga GM, Fogelman AM,. 2009. Apolipoprotein A-I mimetic peptides. Curr Atheroscler Rep 11: 52-57.
46. Van Linthout S, Spillmann F, Schultheiss HP, Tschope C,. 2010. High-density lipoprotein at the interface of type 2 diabetes mellitus and cardiovascular disorders. Curr Pharm Des 16: 1504-1516.
47. Wang G, Hamid T, Keith RJ, Zhou G, Partridge CR, Xiang X, Kingery JR, Lewis RK, Li Q, Rokosh DG, Ford R, Spinale FG, Riggs DW, Srivastava S, Bhatnagar A, Bolli R, Prabhu SD,. 2010. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation 121: 1912-1925.
48. Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, Navab M, Hama S, Hough G, Reddy ST, Soffer D, Rader DJ, Fogelman AM, Schecter A,. 2011. Treatment of patients with cardiovascular disease with L-4F, an Apo-A1 mimetic, did not improve select biomarkers of HDL function. J Lipid Res 52: 361-373.
49. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB,. 2005. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 112: 3066-3072. (Pubitemid 43113437)
50. Witteles RM, Fowler MB,. 2006. Cardiomyopathy of insulin resistance. Heart Fail Clin 2: 13-23.
51. Witteles RM, Fowler MB,. 2008. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51: 93-102.
52. Yndestad A, Damas JK, Oie E, Ueland T, Gullestad L, Aukrust P,. 2007. Role of inflammation in the progression of heart failure. Curr Cardiol Rep 9: 236-241. (Pubitemid 46784419)